Monthly research recap
5-MeO-DMT research: September 2026
What September 2026's 10 new studies found, synthesized from the papers below. All 5-MeO-DMT research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for 5-MeO-DMT, 5-methoxy-N, N-dimethyltryptamine, 5-MeO, bufo alvarius, incilius alvarius, then ranked by relevance.
Research indexed for September 2026 on 5-MeO-DMT is almost entirely preclinical and indirect: single-dose 5-MeO-DMT produced rapid antidepressant-like effects in stressed rodents, and these effects depended on both 5-HT1A and 5-HT2A receptors and on the context of administration, while a qualitative analysis of online reports described transformative subjective experiences and individualized dosing. No human clinical trial of 5-MeO-DMT itself appears in this set, so efficacy, durability, and safety in people remain unestablished, and the one human survey covering 5-MeO-DMT reports no specific outcomes.
Evidence by study
Direction is which way each study's own result points, not our rating of the study. All 10 matching studies were reviewed; the 6 that directly address the question are shown here.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 805. Rapid Antidepressant-Like Effects of 5-MeO-DMT Require Both 5-HT 1A and 5-HT 2A Receptors 2026 | RCT | Supports | 5-MeO-DMT at 10 mg/kg produced rapid antidepressant-like effects in the forced swim test that were blocked by both 5-HT1A and 5-HT2A antagonism but not by 5-HT7 or sigma antagonists, indicating both receptors are necessary. | |
| 515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity 2026 | preclinical experimental study | Mixed | A single 0.5 mg/kg dose of 5-MeO-DMT produced antidepressant-like effects in neutral or positive settings but not in a negative setting, which instead promoted anxiogenic-like responses, with positive-setting effects accompanied by degradation of perineuronal nets around hippocampal parvalbumin interneurons. | |
| 188. A single high-dose acute injection of 5-MeO-DMT reverses stress-induced anhedonia in rats 2026 | preclinical experimental study | Supports | A single 10 mg/kg dose of 5-MeO-DMT reversed chronic mild stress-induced anhedonia and normalized REM sleep reductions, while vehicle-treated stressed rats remained anhedonic. | |
| Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis 2026 | qualitative study | 120 | Supports | Users described introspective, cathartic, and spiritually unifying experiences often viewed as transformative, reported individualized dosing and a distinct tolerance profile, and emphasized preparation, supportive settings, integration, and harm reduction. |
| The Role of Nutrition in Psychedelics Clinical Trials: Key Considerations and Recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 2026 | narrative review | Unclear | Argues that nutritional status, diet, body composition, gut microbiota, and food-drug interactions may plausibly influence 5-MeO-DMT pharmacokinetics, pharmacodynamics, efficacy, or safety, while noting that direct clinical evidence is unavailable. | |
| Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 | cross-sectional survey | Unclear | Describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT, with no specific outcomes, comparisons, or effect sizes reported. |
Points of agreement
- Preclinical studies agree that a single dose of 5-MeO-DMT can produce rapid antidepressant-like behavioral effects in stress or depression models.
- Rodent work converges on serotonergic receptor involvement, with 5-HT1A and 5-HT2A activation both required for the antidepressant-like effect.
- Both rodent and qualitative human-report sources indicate that non-drug context (setting, preparation, support) shapes outcomes.
Conflicts
- The context study found that a negative administration setting abolished antidepressant-like effects and produced anxiogenic-like responses, whereas the receptor study reports antidepressant-like effects without manipulating setting.
- Effective doses differ markedly across preclinical work (0.5 mg/kg in the context study versus 10 mg/kg in the receptor and chronic-stress studies).
Gaps
- No human clinical trial of 5-MeO-DMT itself is represented; human evidence is limited to online self-reports and a survey with no reported outcomes.
- Durability of antidepressant-like effects beyond acute post-dose testing is not established.
- Blinding, expectancy, and placebo control in 5-MeO-DMT research are unaddressed.
- Dose-response relationships, long-term safety, and interactions with serotonergic medications remain unstudied.
- Female and non-rodent populations, and clinical populations with depression, are underrepresented.